-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-150 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-150 in Diabetic Macular Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-150 in Diabetic Macular Edema Drug Details: 4D-150 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-150 in Diabetic Retinopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-150 in Diabetic Retinopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-150 in Diabetic Retinopathy Drug Details: 4D-150 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Redasemtide Trifluoroacetate in Dilated Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Redasemtide Trifluoroacetate in Dilated Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Redasemtide Trifluoroacetate in Dilated Cardiomyopathy Drug Details: Redasemtide trifluoroacetate is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acetylleucine in Tay-Sachs Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acetylleucine in Tay-Sachs Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acetylleucine in Tay-Sachs Disease Drug Details: Acetylleucine (IB-1001) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acetylleucine in Ataxia-Telangiectasia (Louis-Bar Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acetylleucine in Ataxia-Telangiectasia (Louis-Bar Syndrome) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acetylleucine in Ataxia-Telangiectasia (Louis-Bar Syndrome) Drug Details: Acetylleucine (IB-1001) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acetylleucine in Spinocerebellar Ataxia (SCA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acetylleucine in Spinocerebellar Ataxia (SCA) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acetylleucine in Spinocerebellar Ataxia (SCA) Drug Details: Acetylleucine (IB-1001) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2b LA in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2b LA in Hepatitis B report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2b LA in Hepatitis B Drug Details: Ropeginterferon...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-222 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-222 in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nelitolimod Sodium in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nelitolimod Sodium in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nelitolimod Sodium in Hepatocellular Carcinoma Drug Details: Nelitolimod is under...